Home / Health / Tufts Researchers Unveil "Quadruple-Action" Weight Loss Medication
Tufts Researchers Unveil "Quadruple-Action" Weight Loss Medication
8 Sep
Summary
- Tufts University scientists develop new drug targeting 4 hormones for weight loss
- Aims to match effectiveness of bariatric surgery with up to 30% weight loss
- Designed to reduce nausea, muscle loss, and weight regain associated with GLP-1 meds
According to a recent study, researchers at Tufts University have made a breakthrough in the development of a new weight loss medication that aims to outperform existing GLP-1 drugs like Ozempic. The experimental "quadruple-action" drug targets a combination of four hormones - GLP-1, GIP, glucagon, and peptide YY - to achieve long-lasting weight loss of up to 30%, matching the effectiveness of bariatric surgery.
The key innovation is the drug's ability to manage appetite, blood sugar, and energy use without overloading any single hormone pathway. By incorporating GIP, which is known to ease nausea, the researchers hope to reduce the common side effects of nausea, muscle loss, and weight regain associated with current GLP-1 medications.
While the new drug is still in the preclinical stage and has not yet been tested in human trials, the researchers are optimistic about its potential to provide a more comprehensive obesity treatment option. They believe their approach of "nudging four 'dimmer switches' together" could lead to safer and more effective weight management compared to existing therapies.
